These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33519450)

  • 1. The Expiry of Humira
    Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
    Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 3. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of Humira® Biosimilars: Current European Landscape and Future Implications.
    Coghlan J; He H; Schwendeman AS
    J Pharm Sci; 2021 Apr; 110(4):1572-1582. PubMed ID: 33556387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA.
    Gherghescu I; Delgado-Charro MB
    Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33396369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):299-306. PubMed ID: 30945206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
    Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
    Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
    Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
    Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
    Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
    BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
    Barszczewska O; Piechota A
    Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):285-297. PubMed ID: 30945207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 16. Navigating adalimumab biosimilars: an expert opinion.
    Abitbol V; Benkhalifa S; Habauzit C; Marotte H
    J Comp Eff Res; 2023 Nov; 12(11):e230117. PubMed ID: 37855223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Market diffusion of biosimilars in off-patent biologic drug markets across Europe.
    Böhm AK; Steiner IM; Stargardt T
    Health Policy; 2023 Jun; 132():104818. PubMed ID: 37086662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
    Vogler S; Schneider P; Zuba M; Busse R; Panteli D
    Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
    [No Abstract]   [Full Text] [Related]  

  • 19. Biosimilar underutilization alone does not foretell a broken biologics market.
    LaMountain F; Beinfeld MT; Wong W; Kim E; Chambers JD
    Health Aff Sch; 2024 Jul; 2(7):qxae090. PubMed ID: 39071106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.